• Revenue up 9.6% to $19.2 million
• Adjusted EBITDA of $2.6 million, up from $0.3 million
• Net tangible assets per share of 24.26 cents, up from 24.05 cents

Little Green Pharma Ltd reported a 9.6% increase in revenue to $19.2 million and a significant improvement in Adjusted EBITDA to $2.6 million for the half-year ended 30 September 2025. The Group's half-year financial results included record revenues and positive Adjusted EBITDA and operating cash flows, demonstrating the effectiveness of its House of Brands strategy and prudent cost management. Meanwhile, market developments in Germany, the United Kingdom and France validated the Group's long-held strategy of accessing high and low regulatory barrier territories across Europe. The Group's net tangible assets at the end of the half-year were 24.26 cents per share, up from 24.05 cents per share at 31 March 2025. The Group's debt remained low at the end of the half-year at $3.4 million, and its cash position was $2.3 million. The Group's operating cash inflow was $230,000, down from $738,000 in the prior comparative period. Key operational highlights included continued revenue increases in Germany and the United Kingdom, the acquisition of the Health House medicinal cannabis distribution business, and the publication of positive results from the Company's QUEST Initiative clinical studies. The Company also commenced a restructuring project involving automation and offshore driven headcount reduction.